Tilray Sees Cannabis Rescheduling as Gateway to US Medical Market

Tilray Eyes Quick Entry into US Medical Cannabis Market if Federal Reclassification Occurs.

Tilray Brands believes it can get into the medical marijuana business in the U.S. pretty quickly if the Biden administration reclassifies cannabis as a Schedule 3 drug sometime this year, CEO Irwin Simon tells WSJ.

As one of the largest medical cannabis businesses in both Canada and Europe, Tilray has "the expertise in growth, the research and the know-how" to launch medical cannabis operations in the U.S. expeditiously, whether through a greenfield approach or by acquiring an existing player in the States, Simon says.

The CEO says Tilray would target the big markets on both coasts, including California and New York.

For more Cannabis News like this, circle back to 420intel.com!

420 Intel News | 420 Advertising | Cannabis Business News | Medical Marijuana News | Recreational Marijuana News